“Phialogics”: innovative biologics to treat autoimmune diseases
In August 2021, after several years of research at Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, a team of scientists has spun-off and created Phialogics, a preclinical-stage biotechnology company dedicated to the development of innovative biologics to treat autoimmune diseases.
Frankfurt am Main. The immune system is a complex network of organs, cells and proteins that protects organisms from pathogens. In autoimmune diseases, this system is dysbalanced and attacks parts of its own body, leading to severe acute and chronic disorders. In order to treat these diseases, highly innovative approaches are required that can efficiently and selectively stop or prevent organ damage caused by autoimmune processes.
The Fraunhofer ITMP spin-off Phialogics, founded in July 2021 in Frankfurt am Main, Germany, utilizes its know-how in protein engineering to create and develop immune checkpoint activators to rebalance the immune response in autoimmune diseases. Phialogics' disruptive approach aims to maximize therapeutic impact while reducing side effects in the treatment of autoimmunity. Among other things, this should prevent tissue and organ damage leading to multi-organ failure in critical care disorders.
Frankfurt (Germany): In July, Phialogics, a preclinical-stage biotechnology company dedicated to the development of innovative biologics to treat autoimmune disease, was founded in Frankfurt, Germany. The founding team, composed of experienced academic researchers and industry veterans, is excited to bring a new generation of immune-modulatory drugs to patients. Phialogics’ disruptive approach aims to maximize therapeutic impact while reducing side-effects in the treatment of autoimmune diseases.